Mark Kotter is a neurosurgeon, clinician-scientist, and biotech entrepreneur at the University of Cambridge. His clinical work focuses on complex spinal and spinal cord disorders, particularly degenerative cervical myelopathy (DCM). He founded and co-leads the international AO Spine RECODE-DCM initiative, uniting more than 400 researchers across 60 countries to establish global research priorities and standards for DCM.
In parallel, his laboratory at Cambridge explores stem cell programming, regeneration, and ageing biology — work that has led to the creation of several biotech companies, including bit.bio, clock.bio, which together have raised over 300 million USD.
Through his commitment of clinical excellence, translational research, and entrepreneurship, Kotter aims to bridge the gap between biological discovery and surgical innovation, redefining how spinal cord disorders are understood and treated for the benefit of patients.